Chronicle Journal: Finance

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Blueprint Medicines Ord Shs (NQ: BPMC)
79.15 USD  +0.13 (+0.16%)
Official Closing Price  /  Updated: 4:51 PM EDT, Jul 2, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 269,900
Open 80.11
Bid (Size) 79.14 (49)
Ask (Size) 79.34 (7)
Prev. Close 79.02
Today's Range 78.51 - 80.92
52wk Range 43.29 - 102.98
Shares Outstanding 43,837,337
Dividend Yield N/A
Performance
YTD
-3.70%
-3.70%
1 Month
+11.92%
+11.92%
3 Month
+31.06%
+31.06%
6 Month
-3.70%
-3.70%
1 Year
-19.64%
-19.64%
Top News
More News
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on July 1,... Read More
from PR Newswire
Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a New Drug... Read More
from PR Newswire
More News
Read More
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST
from PR Newswire
Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis
from PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
from PR Newswire
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumor
from PR Newswire
Blueprint Medicines to Present at Upcoming Investors Conferences
from PR Newswire
Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020
from PR Newswire
Blueprint Medicines Moves Up In Market Cap Rank, Passing Unum Group
category Stocks
from Market News Video
Notable Wednesday Option Activity: IBM, BPMC, SPG
category Stocks
from Market News Video
Blueprint Medicines Trying To Close In On Key Technical Benchmark
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]